Solutions 4 Wealth Ltd Acquires Shares of 36,085 Galectin Therapeutics Inc. (NASDAQ:GALT)

Solutions 4 Wealth Ltd bought a new position in Galectin Therapeutics Inc. (NASDAQ:GALT) during the 4th quarter, HoldingsChannel reports. The fund bought 36,085 shares of the company’s stock, valued at approximately $60,000.

Several other hedge funds also recently made changes to their positions in GALT. Beacon Capital Management LLC grew its holdings in Galectin Therapeutics by 89.6% in the 4th quarter. Beacon Capital Management LLC now owns 23,905 shares of the company’s stock worth $40,000 after acquiring an additional 11,300 shares during the last quarter. AE Wealth Management LLC raised its stake in shares of Galectin Therapeutics by 72.7% during the third quarter. AE Wealth Management LLC now owns 26,841 shares of the company’s stock valued at $52,000 after acquiring an additional 11,300 shares during the last quarter. Retirement Guys Formula LLC boosted its holdings in shares of Galectin Therapeutics by 87.0% during the fourth quarter. Retirement Guys Formula LLC now owns 21,500 shares of the company’s stock worth $36,000 after purchasing an additional 10,000 shares during the period. Finally, D.A. Davidson & CO. grew its stake in shares of Galectin Therapeutics by 15.2% in the third quarter. D.A. Davidson & CO. now owns 37,825 shares of the company’s stock worth $73,000 after purchasing an additional 5,000 shares during the last quarter. 11.68% of the stock is owned by hedge funds and other institutional investors.

Galectin Therapeutics Stock Down 3.7 %

Shares of NASDAQ:GALT traded down $0.13 on Thursday, hitting $3.37. The company had a trading volume of 250,289 shares, compared to its average volume of 134,129. The firm’s 50-day simple moving average is $2.71 and its two-hundred day simple moving average is $2.15. The firm has a market capitalization of $208.60 million, a price-to-earnings ratio of -4.45 and a beta of 0.72. Galectin Therapeutics Inc. has a 1 year low of $1.28 and a 1 year high of $4.27.

Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Friday, March 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Galectin Therapeutics Inc. will post -0.66 EPS for the current year.

Analyst Ratings Changes

A number of research firms have commented on GALT. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Galectin Therapeutics in a research report on Tuesday, April 9th. StockNews.com upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, April 1st.

Insider Transactions at Galectin Therapeutics

In other news, major shareholder James C. Czirr sold 21,323 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $3.06, for a total value of $65,248.38. Following the completion of the transaction, the insider now owns 5,925,884 shares in the company, valued at approximately $18,133,205.04. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last quarter, insiders bought 4,500 shares of company stock valued at $14,360. Corporate insiders own 52.70% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.